Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bicalutamide |
Synonyms | |
Therapy Description |
Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bicalutamide | Casodex | Hormone - Anti-androgens 54 | Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | CHE | 3 |
NCT03147196 | Phase II | Bicalutamide + Raloxifene Raloxifene Bicalutamide | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Withdrawn | 0 | |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT01420250 | Phase I | Bicalutamide Cabazitaxel | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | Completed | USA | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT02582749 | Phase II | Bicalutamide + Radium Ra 223 dichloride Bicalutamide | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | Terminated | USA | 0 |
NCT02058706 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer | Completed | USA | 0 |
NCT06018116 | Phase II | Bicalutamide | A Canadian Phase II Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer (CANUCK-01) | Withdrawn | CAN | 0 |
NCT02059213 | Phase II | Goserelin Palbociclib Bicalutamide Leuprolide | A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer | Completed | USA | 0 |
NCT00541047 | Phase III | Leuprolide Goserelin Bicalutamide | Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) | Completed | GBR | CAN | 0 |
NCT02799706 | Phase III | Flutamide Degarelix Bicalutamide | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) | Active, not recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BEL | 0 |
NCT06501911 | Phase I | Bicalutamide | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | Not yet recruiting | USA | 0 |
NCT02614859 | Phase II | Bicalutamide Metformin | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients | Completed | USA | 0 |
NCT02366494 | Phase I | Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Active, not recruiting | USA | 0 |
NCT00002651 | Phase III | Bicalutamide Goserelin | Hormone Therapy in Treating Men With Stage IV Prostate Cancer | Completed | CAN | 0 |
NCT02531516 | Phase III | Abiraterone + Apalutamide + Prednisone Bicalutamide | An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | ARG | 7 |
NCT01674270 | Phase II | Bicalutamide Degarelix | Degarelix Neo-Adjuvant Radical Prostatectomy Trial | Completed | CAN | 0 |
NCT02064036 | Phase I | Bicalutamide Goserelin Leuprolide | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate | Completed | USA | 0 |
NCT01809691 | Phase III | Orteronel Bicalutamide | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT00936390 | Phase III | Flutamide Goserelin Leuprolide Triptorelin Bicalutamide | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT05327647 | Phase II | Bicalutamide | A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa) | Recruiting | CAN | 0 |
NCT04025372 | Phase II | Bicalutamide Darolutamide | INTREPId (INTermediate Risk Erection PreservatIon Trial) | Active, not recruiting | USA | 0 |
NCT03458221 | Phase II | Itraconazole Everolimus Letrozole Bicalutamide | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (STAPOVER) | Recruiting | NLD | 0 |
NCT02346253 | Phase Ib/II | Leuprolide Triptorelin Degarelix Bicalutamide Goserelin | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03809000 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) | Active, not recruiting | USA | CAN | 0 |
NCT01342367 | Phase I | Bicalutamide Dutasteride Finasteride | Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | Active, not recruiting | USA | 0 |